EC
NPCE icon

EntryPoint Capital’s Neuropace NPCE Stock Holding History

EntryPoint Capital’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Hold
11,953
– – 0.05% 673
2025
Q4 		$185K Buy
+11,953
New +$160K 0.07% 568
2025
Q2 		– Sell
-27,766
Closed -$341K – 748
2025
Q1 		$341K Buy
+27,766
New +$348K 0.16% 261
2024
Q2 		– Sell
-1,632
Closed -$21.5K – 1385
2024
Q1 		$21.5K Buy
+1,632
New +$23.3K 0.02% 1076

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EntryPoint Capital's NPCE Position: Q1 2026 in Review

EntryPoint Capital held its Neuropace (NPCE) position steady in Q1 2026 at 11,953 shares worth $157K. The position accounts for 0.05% of the portfolio, ranked #673.

EntryPoint Capital first reported a position in NPCE in Q1 2024 and has held it in 4 quarters since. The position peaked at $341K in Q1 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • EntryPoint Capital held 11,953 shares of Neuropace worth $157K as of Q1 2026.
  • EntryPoint Capital left its Neuropace share count unchanged in Q1 2026.
  • Neuropace made up 0.05% of EntryPoint Capital's portfolio in Q1 2026, its #673 holding.
  • EntryPoint Capital first reported a position in Neuropace in Q1 2024 and has held it in 4 quarters since.
  • EntryPoint Capital's Neuropace position peaked at $341K in Q1 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.